Viruses and viral epitopes to which serum IgG antibodies were directed based on the VirScan assay. This figure includes data for 28 participants with serum sample results from both the pre– and post–CD19-CARTx time periods; 2 participants who did not have data for both periods were excluded. (A) Each column depicts whether a participant had IgG for a given virus (indicated in rows) in the pre–CD19-CARTx (light shading) or last post–CD19-CARTx (dark shading) sample; participants are grouped by prior HCT status. (B) Each column depicts the number of epitopes to which IgG antibodies were directed in a participant for a given virus (indicated in rows) in the pre–CD19-CARTx or last post–CD19-CARTx sample; shading is based on a heat map for the number of epitopes, and participants are grouped by prior HCT status. Forest plots showing linear mixed-effects model estimates for the mean change in the total number of viruses (C) and epitopes (D) recognized by IgG. Exploratory subgroup estimates were computed from separate models, including the subgroup variable, the time period (post– vs pre–CD19-CARTx), and their interaction. Participants without a prior HCT had a greater decrement in the total virus and epitope IgG (C-D) compared with participants with a prior HCT, although the differences did not reach statistical significance (interaction P = .07 and .12, respectively). Squares represent the change estimates, and bars indicate the 95% CIs. Dashed vertical reference lines are shown at our prespecified noninferiority margins and at no change.